Literature DB >> 30169110

Atorvastatin, but not pravastatin, inhibits cardiac Akt/mTOR signaling and disturbs mitochondrial ultrastructure in cardiac myocytes.

Joseph C Godoy1, Ingrid R Niesman2, Anna R Busija2, Adam Kassan1,2,3, Jan M Schilling1,2, Anna Schwarz1, Erika A Alvarez4, Nancy D Dalton4, John C Drummond1,2, David M Roth1,2, Georgios Kararigas5,6, Hemal H Patel1,2, Alice E Zemljic-Harpf1,2.   

Abstract

Statins, which reduce LDL-cholesterol by inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, are among the most widely prescribed drugs. Skeletal myopathy is a known statin-induced adverse effect associated with mitochondrial changes. We hypothesized that similar effects would occur in cardiac myocytes in a lipophilicity-dependent manner between 2 common statins: atorvastatin (lipophilic) and pravastatin (hydrophilic). Neonatal cardiac ventricular myocytes were treated with atorvastatin and pravastatin for 48 h. Both statins induced endoplasmic reticular (ER) stress, but only atorvastatin inhibited ERK1/2T202/Y204, AktSer473, and mammalian target of rapamycin signaling; reduced protein abundance of caveolin-1, dystrophin, epidermal growth factor receptor, and insulin receptor-β; decreased Ras homolog gene family member A activation; and induced apoptosis. In cardiomyocyte-equivalent HL-1 cells, atorvastatin, but not pravastatin, reduced mitochondrial oxygen consumption. When male mice underwent atorvastatin and pravastatin administration per os for up to 7 mo, only long-term atorvastatin, but not pravastatin, induced elevated serum creatine kinase; swollen, misaligned, size-variable, and disconnected cardiac mitochondria; alteration of ER structure; repression of mitochondria- and endoplasmic reticulum-related genes; and a 21% increase in mortality in cardiac-specific vinculin-knockout mice during the first 2 months of administration. To our knowledge, we are the first to demonstrate in vivo that long-term atorvastatin administration alters cardiac ultrastructure, a finding with important clinical implications.-Godoy, J. C., Niesman, I. R., Busija, A. R., Kassan, A., Schilling, J. M., Schwarz, A., Alvarez, E. A., Dalton, N. D., Drummond, J. C., Roth, D. M., Kararigas, G., Patel, H. H., Zemljic-Harpf, A. E. Atorvastatin, but not pravastatin, inhibits cardiac Akt/mTOR signaling and disturbs mitochondrial ultrastructure in cardiac myocytes.

Entities:  

Keywords:  Statins; cardiomyocytes; heart failure; oxygen consumption rate; statin-induced myopathy

Mesh:

Substances:

Year:  2018        PMID: 30169110     DOI: 10.1096/fj.201800876R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  5 in total

1.  Tissue-Engineered Human Myobundle System as a Platform for Evaluation of Skeletal Muscle Injury Biomarkers.

Authors:  Alastair Khodabukus; Amulya Kaza; Jason Wang; Neel Prabhu; Richard Goldstein; Vishal S Vaidya; Nenad Bursac
Journal:  Toxicol Sci       Date:  2020-07-01       Impact factor: 4.849

2.  Pravastatin and Gemfibrozil Modulate Differently Hepatic and Colonic Mitochondrial Respiration in Tissue Homogenates from Healthy Rats.

Authors:  Anna Herminghaus; Eric Laser; Jan Schulz; Richard Truse; Christian Vollmer; Inge Bauer; Olaf Picker
Journal:  Cells       Date:  2019-08-27       Impact factor: 6.600

3.  The Mitochondrial Antioxidant SS-31 Modulates Oxidative Stress, Endoplasmic Reticulum Stress, and Autophagy in Type 2 Diabetes.

Authors:  Irene Escribano-López; Aranzazu M de Marañon; Francesca Iannantuoni; Sandra López-Domènech; Zaida Abad-Jiménez; Pedro Díaz; Eva Solá; Nadezda Apostolova; Milagros Rocha; Víctor M Víctor
Journal:  J Clin Med       Date:  2019-08-28       Impact factor: 4.241

4.  Atorvastatin Induces Mitochondria-Dependent Ferroptosis via the Modulation of Nrf2-xCT/GPx4 Axis.

Authors:  Qi Zhang; Hang Qu; Yinghui Chen; Xueyang Luo; Chong Chen; Bing Xiao; Xiaowei Ding; Pengjun Zhao; Yanan Lu; Alex F Chen; Yu Yu
Journal:  Front Cell Dev Biol       Date:  2022-03-03

5.  Pravastatin Administration Alleviates Kanamycin-Induced Cochlear Injury and Hearing Loss.

Authors:  Chang Ho Lee; Jiwon Jeon; So Min Lee; So Young Kim
Journal:  Int J Mol Sci       Date:  2022-04-20       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.